期刊
VACCINE
卷 29, 期 25, 页码 4249-4255出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2011.03.068
关键词
alpha GalCerMPEG; Invariant NKT cell; IFN-gamma
资金
- German Research Council [GRK1441]
One experimental approach for the treatment of allergic reactions is the stimulation of immunoregulatory NKT cells with the synthetic glycolipid alpha galactosylceramide. For a first evaluation of the immunomodulatory potential of alpha GalCerMPEG a human in vitro allergy model was exploited. Acting as an adjuvant, the glycolipid induced an enhanced Th1-biased allergen-specific immune response of autologous lymphocytes. In a mouse model of allergic airway inflammation, alpha GalCerMPEG-activated NKT cells promoted a cytokine environment in the spleen, leading to priming of Th1 cells. The shift towards a Th1-dominated allergen-specific immune response thus might mediate the abrogation of allergic airway inflammation and thereby might provide a valid option for therapeutic intervention. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据